LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations

CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date

Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC

Investigators Report Efficacy, Safety Analysis of Tarlatamab in SCLC Patients With or Without Baseline Brain Metastases

Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC

Osimertinib Plus Chemotherapy May Improve CNS Activity in Advanced EGFR-positive NSCLC

Gender Disparity in Lung Cancer

BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population

Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2